ESMO 2022: Fruquintinib Promising as Treatment Option in Refractory Metastatic Colorectal Cancer
Patients with refractory mCRC showed significant improvement in overall survival with the tyrosine kinase inhibitor
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.